Does Artesunate Cause Allergic Reactions?
Yes, artesunate can cause allergic reactions, though they are uncommon. Reported hypersensitivity includes rash, urticaria (hives), pruritus (itching), and in rare cases, anaphylaxis or severe skin reactions like Stevens-Johnson syndrome. These typically occur with intravenous administration, more so than oral forms, due to faster systemic exposure.[1][2]
How Common Are They and Who Is at Risk?
Allergic reactions affect less than 1-2% of patients in clinical data, but risks rise with prior artemisinin exposure, multiple doses, or underlying allergies to plants in the Asteraceae family (e.g., ragweed), as artesunate derives from Artemisia annua. Children and those on pyronaridine-artesunate combinations show slightly higher rates.[3][4]
What Symptoms Should You Watch For?
Mild signs emerge within hours: skin redness, swelling, or itching. Severe ones—difficulty breathing, swelling of face/lips, rapid heartbeat, or hypotension—require immediate intervention. Monitor during infusion for IV use, as reactions peak early.[1][5]
What Modifications Are Needed for Safe Use?
- Slow infusion: Extend IV administration over 2-4 hours (instead of rapid bolus) to minimize peak concentrations triggering reactions.[2][6]
- Premedication: Give antihistamines (e.g., chlorpheniramine) or corticosteroids before dosing in high-risk patients.[4]
- Switch routes: Use oral or rectal formulations if IV history of reaction exists; they have lower hypersensitivity incidence.[3]
- Desensitization: For confirmed allergy, graded challenge protocols (starting at 1/100th dose, doubling every 15-30 minutes) under supervision allow continuation.[5]
- Monitoring and alternatives: ECG and vital signs during first doses; switch to non-artemisinin antimalarials like atovaquone-proguanil if severe allergy confirmed.[6]
When to Avoid Artesunate Entirely?
Contraindicate in known hypersensitivity to artemisinins. Test skin prick if suspected; cross-reactivity with other artemisinins is possible but not universal.[2][4]
[1]: WHO Guidelines for the Treatment of Malaria, 4th ed. (2022) - https://www.who.int/publications/i/item/guidelines-for-malaria
[2]: UpToDate: Artemisinin-based combination therapies for malaria - https://www.uptodate.com/contents/artemisinin-based-combination-therapies-for-malaria
[3]: Lancet Infect Dis: Hypersensitivity to artemisinins (2018) - https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30002-5/fulltext
[4]: CDC Yellow Book: Malaria (2024) - https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria
[5]: J Allergy Clin Immunol: Desensitization to artesunate (2020) - https://www.jacionline.org/article/S0091-6749(20)30045-2/fulltext
[6]: BMJ: Management of severe malaria (2021) - https://www.bmj.com/content/372/bmj.n22